426 related articles for article (PubMed ID: 27578103)
1. The nocebo effect in the context of statin intolerance.
Tobert JA; Newman CB
J Clin Lipidol; 2016; 10(4):739-747. PubMed ID: 27578103
[TBL] [Abstract][Full Text] [Related]
2. Introducing the 'Drucebo' effect in statin therapy: a systematic review of studies comparing reported rates of statin-associated muscle symptoms, under blinded and open-label conditions.
Penson PE; Mancini GBJ; Toth PP; Martin SS; Watts GF; Sahebkar A; Mikhailidis DP; Banach M;
J Cachexia Sarcopenia Muscle; 2018 Dec; 9(6):1023-1033. PubMed ID: 30311434
[TBL] [Abstract][Full Text] [Related]
3. Muscle and statins: from toxicity to the nocebo effect.
Pedro-Botet J; Climent E; Benaiges D
Expert Opin Drug Saf; 2019 Jul; 18(7):573-579. PubMed ID: 31070941
[TBL] [Abstract][Full Text] [Related]
4. New insights into managing symptoms during statin therapy.
Robinson JG
Prog Cardiovasc Dis; 2019; 62(5):390-394. PubMed ID: 31669768
[TBL] [Abstract][Full Text] [Related]
5. SAMSON and the Nocebo Effect: Management of Statin Intolerance.
Krishnamurthy A; Bradley C; Ascunce R; Kim SM
Curr Cardiol Rep; 2022 Sep; 24(9):1101-1108. PubMed ID: 35759168
[TBL] [Abstract][Full Text] [Related]
6. [How to cope with the nocebo effects of statins?].
Lafeber M; Evers AWM; Klok FA
Ned Tijdschr Geneeskd; 2023 Mar; 167():. PubMed ID: 36920298
[TBL] [Abstract][Full Text] [Related]
7. Management of patients with statin intolerance.
Martirossian AN; Goldberg AC
Best Pract Res Clin Endocrinol Metab; 2023 May; 37(3):101714. PubMed ID: 36345572
[TBL] [Abstract][Full Text] [Related]
8. NLA scientific statement on statin intolerance: a new definition and key considerations for ASCVD risk reduction in the statin intolerant patient.
Cheeley MK; Saseen JJ; Agarwala A; Ravilla S; Ciffone N; Jacobson TA; Dixon DL; Maki KC
J Clin Lipidol; 2022; 16(4):361-375. PubMed ID: 35718660
[TBL] [Abstract][Full Text] [Related]
9. Side Effect Patterns in a Crossover Trial of Statin, Placebo, and No Treatment.
Howard JP; Wood FA; Finegold JA; Nowbar AN; Thompson DM; Arnold AD; Rajkumar CA; Connolly S; Cegla J; Stride C; Sever P; Norton C; Thom SAM; Shun-Shin MJ; Francis DP
J Am Coll Cardiol; 2021 Sep; 78(12):1210-1222. PubMed ID: 34531021
[TBL] [Abstract][Full Text] [Related]
10. [Myalgia and statins: Separating the true from the false].
Blacher J; Bruckert E; Farnier M; Ferrières J; Henry P; Krempf M; Mourad JJ
Presse Med; 2019 Oct; 48(10):1059-1064. PubMed ID: 31473026
[TBL] [Abstract][Full Text] [Related]
11. Statin tolerability: In defence of placebo-controlled trials.
Tobert JA; Newman CB
Eur J Prev Cardiol; 2016 May; 23(8):891-6. PubMed ID: 26318980
[TBL] [Abstract][Full Text] [Related]
12. Statin Safety and Associated Adverse Events: A Scientific Statement From the American Heart Association.
Newman CB; Preiss D; Tobert JA; Jacobson TA; Page RL; Goldstein LB; Chin C; Tannock LR; Miller M; Raghuveer G; Duell PB; Brinton EA; Pollak A; Braun LT; Welty FK;
Arterioscler Thromb Vasc Biol; 2019 Feb; 39(2):e38-e81. PubMed ID: 30580575
[TBL] [Abstract][Full Text] [Related]
13. A Review of Statin Intolerance: a Focus on Statin-Attributed Muscle Symptoms.
Orringer CE; Grant JK; Tokgozoglu L
Curr Atheroscler Rep; 2022 Nov; 24(11):839-847. PubMed ID: 36001213
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of alirocumab vs ezetimibe in statin-intolerant patients, with a statin rechallenge arm: The ODYSSEY ALTERNATIVE randomized trial.
Moriarty PM; Thompson PD; Cannon CP; Guyton JR; Bergeron J; Zieve FJ; Bruckert E; Jacobson TA; Kopecky SL; Baccara-Dinet MT; Du Y; Pordy R; Gipe DA;
J Clin Lipidol; 2015; 9(6):758-769. PubMed ID: 26687696
[TBL] [Abstract][Full Text] [Related]
15. Examining the Nocebo Effect of Statins Through Statin Adverse Events Reported in the Food and Drug Administration Adverse Event Reporting System.
Moon J; Cohen Sedgh R; Jackevicius CA
Circ Cardiovasc Qual Outcomes; 2021 Jan; 14(1):e007480. PubMed ID: 33161769
[TBL] [Abstract][Full Text] [Related]
16. Intolerance upon statin rechallenge: A systematic review and meta-analysis of randomized controlled trials.
Kraut R; Wierenga F; Molstad E; Korownyk C; Perry D; Dennett L; Garrison S
PLoS One; 2023; 18(12):e0295857. PubMed ID: 38128013
[TBL] [Abstract][Full Text] [Related]
17. Incidence of muscle symptoms in placebo arm among statin-intolerant patients: a systematic review with meta-analysis.
Louro R; Gouveia E Melo R; Ruivo J; Almeida AG; Pinto FJ; Caldeira D
Expert Rev Cardiovasc Ther; 2023; 21(11):887-894. PubMed ID: 37916684
[TBL] [Abstract][Full Text] [Related]
18. Step-by-step diagnosis and management of the nocebo/drucebo effect in statin-associated muscle symptoms patients: a position paper from the International Lipid Expert Panel (ILEP).
Penson PE; Bruckert E; Marais D; Reiner Ž; Pirro M; Sahebkar A; Bajraktari G; Mirrakhimov E; Rizzo M; Mikhailidis DP; Sachinidis A; Gaita D; Latkovskis G; Mazidi M; Toth PP; Pella D; Alnouri F; Postadzhiyan A; Yeh HI; Mancini GBJ; von Haehling S; Banach M;
J Cachexia Sarcopenia Muscle; 2022 Jun; 13(3):1596-1622. PubMed ID: 35969116
[TBL] [Abstract][Full Text] [Related]
19. Effect of a monoclonal antibody to PCSK9 on low-density lipoprotein cholesterol levels in statin-intolerant patients: the GAUSS randomized trial.
Sullivan D; Olsson AG; Scott R; Kim JB; Xue A; Gebski V; Wasserman SM; Stein EA
JAMA; 2012 Dec; 308(23):2497-506. PubMed ID: 23128163
[TBL] [Abstract][Full Text] [Related]
20. Does Googling lead to statin intolerance?
Khan S; Holbrook A; Shah BR
Int J Cardiol; 2018 Jul; 262():25-27. PubMed ID: 29706390
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
